Based on previous studies in our laboratory which demonstrated that inhibition of 5-Lox kills a range of prostate cancer cell lines without regard to their androgen receptor status, we hypothesized that 5-Lox may be a potential target for therapy of heterogeneous lethal forms of prostate cancer as well. The gene discussed is AR; the disease is prostate carcinoma.